CMBA
MRVI icon

C.M. Bidwell & Associates’s Maravai LifeSciences MRVI Stock Holding History

C.M. Bidwell & Associates’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,090
Closed -$31K – 518
2022
Q2 		$31K Hold
1,090
– – 0.02% 311
2022
Q1 		$38K Buy
+1,090
New +$36.5K 0.02% 313

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

C.M. Bidwell & Associates's MRVI Position: Q3 2022 in Review

C.M. Bidwell & Associates sold out of Maravai LifeSciences (MRVI) in Q3 2022, closing a stake of 1,090 shares — an estimated $31K sold.

C.M. Bidwell & Associates first reported a position in MRVI in Q1 2022 and held it in 2 quarters. The position peaked at $38K in Q1 2022. 202 funds tracked by Wall St. Rank hold MRVI as of Q3 2022.

  • C.M. Bidwell & Associates reported no remaining Maravai LifeSciences position as of Q3 2022 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 1,090 Maravai LifeSciences shares in Q3 2022, an estimated $31K.
  • C.M. Bidwell & Associates first reported a position in Maravai LifeSciences in Q1 2022 and held it in 2 quarters.
  • C.M. Bidwell & Associates's Maravai LifeSciences position peaked at $38K in Q1 2022.
  • 202 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2022.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2022, filed 14 Nov 2022.